Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing

Aligos Therapeutics, Inc.

2023-Q2 EPS reported -$0.97 revenue$4,434,000

Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.
Cash $90.8M at June 30, 2023, down from $125.8M; sufficient through end 2024.
NASH candidate ALG-055009 Phase 1 complete; Phase 2a protocol filing expected Q4 2023; topline data Q4 2024.
COVID-19 protease inhibitor ALG-097558: first-in-human dosing ongoing; topline data H1 2024.
Agreement in principle with Janssen to resolve litigation; case stayed July 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aligos Therapeutics, Inc. reported three months ended June 30, 2023 results: net income $18.8 million, EPS $(0.43).

Period: three months ended June 30, 2023
Net income: $18.8 million
EPS: $(0.43)
Result: reported results

Exact text from the filing

Net losses for the three months ended June 30, 2023, were $18.8 million or basic and diluted net loss per common share of $(0.43), compared to net losses of $19.9 million or basic and diluted net loss per common share of $(0.47) for the three months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-004975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.